GeneFerm Biotechnology Co Ltd (1796) — Capital Reinvestment Ratio
GeneFerm Biotechnology Co Ltd (1796) has a Capital Reinvestment Ratio of 4.13x as of June 2025, meaning it reinvests 4% of its operating cash flow (NT$1.45 Million) in capital expenditures (NT$5.98 Million). See 1796 net asset quality index to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
GeneFerm Biotechnology Co Ltd Capital Reinvestment Ratio (2017–2024)
This chart tracks GeneFerm Biotechnology Co Ltd's Capital Reinvestment Ratio across 8 annual periods. Check GeneFerm Biotechnology Co Ltd (1796) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for GeneFerm Biotechnology Co Ltd (2017–2024)
Year-by-year Capital Reinvestment Ratio for GeneFerm Biotechnology Co Ltd from 2017 to 2024. For live market cap and broader valuation context, see GeneFerm Biotechnology Co Ltd market cap and net worth.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 2.81x | NT$8.09 Million | NT$22.70 Million | ▲ +647.8% |
| 2023 | 0.38x | NT$190.31 Million | NT$71.40 Million | ▼ -83.5% |
| 2022 | 2.27x | NT$122.43 Million | NT$278.42 Million | ▲ +75.3% |
| 2021 | 1.30x | NT$112.23 Million | NT$145.61 Million | ▼ -11.1% |
| 2020 | 1.46x | NT$56.42 Million | NT$82.32 Million | ▼ -60.7% |
| 2019 | 3.72x | NT$14.69 Million | NT$54.57 Million | ▲ +443.5% |
| 2018 | 0.68x | NT$42.14 Million | NT$28.81 Million | ▼ -24.3% |
| 2017 | 0.90x | NT$61.08 Million | NT$55.16 Million | — |